Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
Top Line Data Expected Year-End 2024
PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (LIPO) ("Lipella" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapies for chronic skin conditions and rare diseases, today announced that it has dosed the first two patients in its Phase 2a OLP clinical trial of LP-310, a potential treatment for oral lichen planus ("OLP").
Lipella's Phase 2a trial is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study involving adult male and female subjects experiencing symptomatic Oral Lichen.
The primary objective of the trial is to evaluate the safety and tolerability of LP-310 and to identify the maximum tolerated dose (MTD) and determine the recommended dose for the Phase 2b clinical trial. Secondary objectives include evaluating the efficacy of LP-310 in reducing the signs and symptoms of OLP, as well as assessing the pharmacokinetic and pharmacodynamic properties of LP-310.
"We are excited to have dosed the first two patients in our Phase 2a trial of LP-310," said Dr. William J. Lis, Chief Medical Officer of Lipella. "OLP is a chronic and debilitating condition that affects millions of people worldwide, and there is a significant need for new treatment options. We believe that LP-310 has the potential to be a safe and effective treatment for OLP, and we look forward to the results of this trial."
Lipella expects to report top-line data from the Phase 2a trial by the end of 2024.
Comments